Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Launay-Vacher

Showing results (21-30 of 126) with videos related to

Pageof 13
Sort By:
Current Pharmaceutical Design|December 8, 2004
Antiretroviral drugs and the kidney: dosage adjustment and renal toleranceHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|November 25, 2003
Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysisHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
AIDS (London, England)|May 4, 2005
Fanconi syndrome associated with didanosine therapyHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
ESMO Open|November 16, 2016
Renal insufficiency and cancer treatmentsVincent Launay-Vacher, Nicolas Janus, Gilbert Deray
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 28, 2005
Thalidomide for the nephrologistHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
International Journal of Clinical Pharmacy|March 3, 2012
European Society of Clinical Pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargonAnna Carollo, André Rieutord, Vincent Launay-Vacher, et al.
Bulletin Du Cancer|April 21, 2012
[Iron deficiency and anemia in oncology]Florian Scotté, Vincent Launay-Vacher, Isabelle Ray-Coquard
Bulletin Du Cancer|December 3, 2011
[How to evaluate renal function in cancer patients]Vincent Launay-Vacher, Sarah Zimner-Rapuch, Olivier Moranne
Targeted Oncology|January 18, 2012
Colony stimulating factors (CSF) biosimilars. Progress?Florian Scotté, Vincent Launay-Vacher, Jean-Baptiste Rey
Kidney International|December 1, 2005
Thrombocytopenia induced by nicotinamide in hemodialysis patientsJacques B Rottembourg, Vincent Launay-Vacher, Julien Massard
Pageof 13

Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Current Pharmaceutical Design|December 8, 2004
Antiretroviral drugs and the kidney: dosage adjustment and renal toleranceHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|November 25, 2003
Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysisHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
AIDS (London, England)|May 4, 2005
Fanconi syndrome associated with didanosine therapyHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
ESMO Open|November 16, 2016
Renal insufficiency and cancer treatmentsVincent Launay-Vacher, Nicolas Janus, Gilbert Deray
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 28, 2005
Thalidomide for the nephrologistHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
International Journal of Clinical Pharmacy|March 3, 2012
European Society of Clinical Pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargonAnna Carollo, André Rieutord, Vincent Launay-Vacher, et al.
Bulletin Du Cancer|April 21, 2012
[Iron deficiency and anemia in oncology]Florian Scotté, Vincent Launay-Vacher, Isabelle Ray-Coquard
Bulletin Du Cancer|December 3, 2011
[How to evaluate renal function in cancer patients]Vincent Launay-Vacher, Sarah Zimner-Rapuch, Olivier Moranne
Targeted Oncology|January 18, 2012
Colony stimulating factors (CSF) biosimilars. Progress?Florian Scotté, Vincent Launay-Vacher, Jean-Baptiste Rey
Kidney International|December 1, 2005
Thrombocytopenia induced by nicotinamide in hemodialysis patientsJacques B Rottembourg, Vincent Launay-Vacher, Julien Massard
Pageof 13